An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins

Abstract Aims Brugada syndrome (BrS) is characterized by a unique electrocardiogram (ECG) pattern and life-threatening arrhythmias. However, the Type 1 Brugada ECG pattern is often transient, and a genetic cause is only identified in <25% of patients. We sought to identify an additional biomarker...

Full description

Saved in:

Bibliographic Details
Published in:	European heart journal Vol. 41; no. 30; pp. 2878 - 2890
Main Authors:	Chatterjee, Diptendu, Pieroni, Maurizio, Fatah, Meena, Charpentier, Flavien, Cunningham, Kristopher S, Spears, Danna A, Chatterjee, Dipashree, Suna, Gonca, Bos, J Martjin, Ackerman, Michael J, Schulze-Bahr, Eric, Dittmann, Sven, Notarstefano, Pasquale G, Bolognese, Leonardo, Duru, Firat, Saguner, Ardan M, Hamilton, Robert M
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 07-08-2020
Subjects:	Arrhythmias, Cardiac Autoantibodies Brugada Syndrome - diagnosis Electrocardiography Heart Ventricles Humans Keratin Biomarker Brugada syndrome Actin Autoantibody Connexin-43 Perinexus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Aims Brugada syndrome (BrS) is characterized by a unique electrocardiogram (ECG) pattern and life-threatening arrhythmias. However, the Type 1 Brugada ECG pattern is often transient, and a genetic cause is only identified in <25% of patients. We sought to identify an additional biomarker for this rare condition. As myocardial inflammation may be present in BrS, we evaluated whether myocardial autoantibodies can be detected in these patients. Methods and results For antibody (Ab) discovery, normal human ventricular myocardial proteins were solubilized and separated by isoelectric focusing (IEF) and molecular weight on two-dimensional (2D) gels and used to discover Abs by plating with sera from patients with BrS and control subjects. Target proteins were identified by mass spectrometry (MS). Brugada syndrome subjects were defined based on a consensus clinical scoring system. We assessed discovery and validation cohorts by 2D gels, western blots, and ELISA. We performed immunohistochemistry on myocardium from BrS subjects (vs. control). All (3/3) 2D gels exposed to sera from BrS patients demonstrated specific Abs to four proteins, confirmed by MS to be α-cardiac actin, α-skeletal actin, keratin, and connexin-43, vs. 0/8 control subjects. All (18/18) BrS subjects from our validation cohorts demonstrated the same Abs, confirmed by western blots, vs. 0/24 additional controls. ELISA optical densities for all Abs were elevated in all BrS subjects compared to controls. In myocardium obtained from BrS subjects, each protein, as well as SCN5A, demonstrated abnormal protein expression in aggregates. Conclusion A biomarker profile of autoantibodies against four cardiac proteins, namely α-cardiac actin, α-skeletal actin, keratin, and connexin-43, can be identified from sera of BrS patients and is highly sensitive and specific, irrespective of genetic cause for BrS. The four involved proteins, along with the SCN5A-encoded Nav1.5 alpha subunit are expressed abnormally in the myocardium of patients with BrS.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0195-668X 1522-9645 1522-9645
DOI:	10.1093/eurheartj/ehaa383